


Atty Docket No.: R0142B-REG
USSN: 10/663,335Claim Listing

1. (Currently Amended) A compound of the formula:



or a pharmaceutically acceptable salt thereof,

wherein

n is 0, 1 or 2;

p is 1 or 2;

R1 is aryl;

R2 is a heterocyclyl;

R3 is hydrogen[1,] or alkyl, or $\text{C}(\text{=O})-\text{R}^5$, where R^5 is alkyl, alkoxy, aryl, or aryloxy; and

each R4 is independently hydrogen, hydroxy, cyano, alkyl, alkoxy, thioalkyl, alkylthio, halo, haloalkyl, hydroxyalkyl, nitro, alkoxy carbonyl, alkyl carbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, amino, alkylamino, dialkylamino, alkyl(aryl)amino, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyl(alkylamino), alkylaminosulfonyl, alkylsulfonylamino or methylenedioxy.

2. (Original) The compound according to Claim 1, wherein p is 1 and R4 is located at the 6-position of the indole ring system.

3. (Original) The compound according to Claim 1, wherein R2 is optionally substituted piperazin-1-yl or optionally substituted piperidin-4-yl.

Atty Docket No.: R0142B-REG
USSN: 10/663,335

4. (Original) The compound according to Claim 3, wherein R² is piperazin-1-yl, 4-methylpiperazin-1-yl, 3,5-dimethylpiperazin-1-yl, N-methyl piperidin-4-yl or piperidin-4-yl.

5. (Original) The compound according to Claim 4, wherein R² is 4-methylpiperazin-1-yl.

6. (Previously presented) The compound according to Claim 3, wherein R¹ is optionally substituted phenyl.

7. (Currently Amended) The compound according to Claim 6, wherein R¹ is ~~thien-2-yl or~~ phenyl which is optionally substituted with alkyl, halo, or haloalkyl.

8. (Previously presented) The compound according to Claim 7, wherein R¹ is phenyl, 2,3-dichlorophenyl, 2-fluorophenyl, 2-methylphenyl, 2-trifluoromethylphenyl, or 3-bromophenyl.

9. (Canceled)

10. (Currently Amended) The compound according to Claim 9, wherein R³ is hydrogen[,] or methyl or C(=O) R⁵, where R⁵ is alkoxy.

11. (Currently Amended) The compound according to Claim 1, wherein R¹ is phenyl which is optionally mono- or di-substituted independently with alkyl, halo, or haloalkyl.

12. (Previously presented) The compound according to Claim 11, wherein R¹ is phenyl, 2,3-dichlorophenyl, 2-fluorophenyl, 2-methylphenyl, 2-trifluoromethylphenyl, or 3-bromophenyl.

13. (Canceled)

Atty Docket No.: R0142B-REG
USSN: 10/663,335

14. (Currently Amended) The compound according to Claim 43 11, wherein R² is optionally substituted piperazin-1-yl or optionally substituted piperidin-4-yl.

15. (Original) The compound according to Claim 14, wherein R² is piperazin-1-yl, 4-methylpiperazin-1-yl, 3,5-dimethylpiperazin-1-yl, N-methyl piperidin-4-yl or piperidin-4-yl.

16. (Currently Amended) The compound according to Claim 15, wherein R³ is hydrogen[.] or methyl or ~~C(=O) R⁵~~, where R⁵ is alkoxy.


17. (Canceled)

18. (Currently Amended) The compound according to Claim 47 15, wherein R¹ is thiienyl or phenyl which is optionally mono- or di-substituted independently alkyl, halo, haloalkyl.

19. (Original) The compound according to Claim 18, wherein R² is optionally substituted piperazin-1-yl or optionally substituted piperidin-4-yl.

20. (Original) The compound according to Claim 19, wherein R³ is hydrogen[.] or methyl or ~~C(=O) R⁵~~, where R⁵ is alkoxy.

21. (Currently Amended) A method for producing a compound of claim 1, said method comprising contacting a substituted indole of the formula:




wherein R³ is alkyl or ~~C(=O) R⁵~~ and p, R² and R⁴ are as recited in claim 1,

- (i) with a base to produce a deprotonated indole; and
- (ii) contacting the deprotonated indole with a sulfonylating agent of the formula:

Atty Docket No.: R0142B-REG
USSN: 10/663,335

$Y-SO_2-R^1$, where Y is halide and R^1 is as recited in claim 1, or a disulfide agent of the formula: $R^1-S-S-R^1$ to produce a 2-substituted indole of the formula:



- (iii) optionally oxidizing the sulfur with an oxidizing agent; and
- (iv) optionally removing R^3 to produce the compound of claim 1.

22. (Withdrawn) The method of Claim 21, wherein Y is fluorine.

23. (Original) A composition comprising:

- (a) a therapeutically effective amount of a compound of Claim 1; and
- (b) a pharmaceutically acceptable carrier.

24. (Withdrawn) A method for treating a CNS disease state in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound of Claim 1.

25. (Withdrawn) The method of Claim 24, wherein the disease state comprises psychoses, schizophrenia, manic depressions, neurological disorders, memory disorders, attention deficit disorder, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease.

26. (Withdrawn) A method for treating a disorder of the gastrointestinal tract in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound of Claim 1.

27. (Withdrawn) A method for treating obesity in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound of Claim 1.